3191 results for «345»
3191 results
Introducing the next era of coronary intravascular lithotripsy: an aero-volution in calcium modification
27 Feb 2026 – From Euro4C Annual Meeting
Explore the next era of coronary intravascular lithotripsy featuring innovative technology for calcium modification. This session covers the unique mechanism of action, practical application in complex cases, and recent clinical evidence supporting its safety and efficacy.
Hot topics and evidence on structural interventions in 2025 and 2026
14 Feb 2026 – From PCR Tokyo Valves 2026
Delve into the emerging clinical evidence and key hot topics shaping transcatheter interventions for aortic, mitral, and tricuspid valve diseases anticipated to influence clinical practice in 2025 and 2026. This session reviews stroke prevention, valve interventions across the three valves, and integrates recent and upcoming data...
Novel Hertz Contact intravascular lithotripsy: calcium fragmentation with zero trade-offs
27 Feb 2026 – From Euro4C Annual Meeting
This session introduces the novel Hertz Contact intravascular lithotripsy system, designed for effective calcium fragmentation without trade-offs. It covers lesion types amenable to treatment, system mechanism, optimization tips, and discusses real-world cases along with supporting clinical trial evidence.
Prevention and management of TAVI complications
14 Feb 2026 – From PCR Tokyo Valves 2026
This session addresses the prevention and management of major complications associated with transcatheter aortic valve implantation (TAVI). Attendees will gain a detailed understanding of mechanisms behind cerebral infarction, haemolysis, valve infolding, pacemaker implantation, and valve migration, along with expert strategies for recognition, decision-making, and bailout techniques...
Primary mitral TEER in small anatomy - LIVE case
15 Feb 2026 – From PCR Tokyo Valves 2026
An 89-year-old male with diabetes mellitus, hypertension, chronic kidney disease (eGFR: 46), and CAD with a history of NSTEMI and CTO of the RCA, presented with symptomatic primary mitral regurgitation (P1–P2 prolapse) and preserved LV function (56%).
One Pascal ACE device was implanted.
LIVE Educational Case from Nagoya...
Guidelines update
15 Feb 2026 – From PCR Tokyo Valves 2026
This session reviews the latest updates in the ESC/EACTS guidelines for structural heart disease, emphasizing their clinical implications and future trends. Participants will gain understanding of changes in aortic, mitral, and tricuspid valve recommendations, including new age cutoffs, asymptomatic disease management, and the evolving role of...
Future devices and techniques for structural heart disease
15 Feb 2026 – From PCR Tokyo Valves 2026
This session surveys the future landscape of structural heart disease treatment, addressing current limitations in transcatheter valve technologies and presenting emerging devices and techniques for aortic, mitral, and tricuspid valves. Attendees will gain insights into innovations poised to transform therapeutic options for structural heart disease.
PCR London Valves 2021 – Welcome message
Everolimus-eluting stents or bypass surgery for mutivessel coronary artery disease: 10-year outcomes of multicenter randomized controlled BEST trial
20 Sep 2022
Nicola Ryan provides her take on the BEST trial which was presented by Jung-Min Ahn at TCT 2022.
It is a randomised, multicentre, non-inferiority trial comparing PCI with second-generation everolimus-eluting stents and CABG in patients with non-left main multivessel coronary artery disease. At two-year follow-up PCI was shown...
Author
Real-world outcomes with the PASCAL Platform in TR
03 Dec 2021
The PASCAL platform, comprising the PASCAL and PASCAL Ace implants, received its CE mark for TR in May 2020 and has been shown to be an effective and safe treatment option for patients with TR.3,4,6 Professor Jörg Hausleiter and Dr Mirjam Wild now describe their single-centre experience...
One-year results of the Clasp TR Study: Transcatheter treatment of tricuspid regurgitation
22 Mar 2022
Alessandro Sticchi and Luigi Biasco provide their take on the 1-year results of the CLASP TR study which were presented by Dr Adan Greenbaum, co-director of the Emory Structural Heart and Valve Center (Atlanta, GA) during the 2022 American College of Cardiology annual Congress held in Washington D.C.
Author
Author
